Nautilus Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Nautilus Biotechnology, Inc. (NAUT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.61 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-28.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-28
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.74M shares, a 8.86% increase year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.88M shares, a 1.10% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 119.85K shares, a 16.77% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 46.00K shares, a 91.50% decline year-over-year.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.66M shares, a 10.94% decline from fiscal 2024.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 4.11M shares, a 2.47% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.01M shares, a 14.27% decline from fiscal 2022.
- Nautilus Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 4.68M shares, a 9.05% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.74M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-28 | 3.61M shares 10-Q · filed 2026-07-28 | 3.73M shares derived: sum of 3 quarters · filed 2026-07-28 | 3.78M shares derived: sum of 4 quarters · filed 2026-07-28 |
| 2026-03-31 | 1.88M shares 10-Q · filed 2026-04-28 | 2.00M shares derived: sum of 2 quarters · filed 2026-04-28 | 2.04M shares derived: sum of 3 quarters · filed 2026-04-28 | 3.64M shares derived: sum of 4 quarters · filed 2026-04-28 |
| 2025-12-31 | 119.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 165.85K shares derived: sum of 2 quarters · filed 2026-02-26 | 1.76M shares derived: sum of 3 quarters · filed 2026-02-26 | 3.66M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 46.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | 1.64M shares derived: sum of 2 quarters · filed 2025-10-28 | 3.54M shares 10-Q · filed 2025-10-28 | 3.68M shares derived: sum of 4 quarters · filed 2025-10-28 |
| 2025-06-30 | 1.60M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | 3.49M shares 10-Q · filed 2025-07-31 | 3.64M shares derived: sum of 3 quarters · filed 2025-07-31 | 4.18M shares derived: sum of 4 quarters · filed 2025-07-31 |
| 2025-03-31 | 1.90M shares 10-Q · filed 2025-04-29 | 2.04M shares derived: sum of 2 quarters · filed 2025-04-29 | 2.58M shares derived: sum of 3 quarters · filed 2025-04-29 | 4.00M shares derived: sum of 4 quarters · filed 2025-04-29 |
| 2024-12-31 | 144.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 685.00K shares derived: sum of 2 quarters · filed 2025-02-27 | 2.11M shares derived: sum of 3 quarters · filed 2025-02-27 | 4.11M shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 541.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | 1.96M shares derived: sum of 2 quarters · filed 2024-10-29 | 3.96M shares 10-Q · filed 2024-10-29 | 4.35M shares derived: sum of 4 quarters · filed 2024-10-29 |
| 2024-06-30 | 1.42M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-30 | 3.42M shares 10-Q · filed 2024-07-30 | 3.81M shares derived: sum of 3 quarters · filed 2024-07-30 | 3.92M shares derived: sum of 4 quarters · filed 2024-07-30 |
| 2024-03-31 | 2.00M shares 10-Q · filed 2024-04-30 | 2.39M shares derived: sum of 2 quarters · filed 2024-04-30 | 2.50M shares derived: sum of 3 quarters · filed 2024-04-30 | 3.73M shares derived: sum of 4 quarters · filed 2024-04-30 |
| 2023-12-31 | 382.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 495.90K shares derived: sum of 2 quarters · filed 2024-02-28 | 1.73M shares derived: sum of 3 quarters · filed 2024-02-28 | 4.01M shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 113.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | 1.35M shares derived: sum of 2 quarters · filed 2023-10-31 | 3.63M shares 10-Q · filed 2023-10-31 | 3.86M shares derived: sum of 4 quarters · filed 2023-10-31 |
| 2023-06-30 | 1.23M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | 3.51M shares 10-Q · filed 2023-08-02 | 3.74M shares derived: sum of 3 quarters · filed 2023-08-02 | 4.15M shares derived: sum of 4 quarters · filed 2023-08-02 |
| 2023-03-31 | 2.28M shares 10-Q · filed 2023-05-02 | 2.51M shares derived: sum of 2 quarters · filed 2023-05-02 | 2.92M shares derived: sum of 3 quarters · filed 2023-05-02 | 5.01M shares derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | 229.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 639.50K shares derived: sum of 2 quarters · filed 2023-02-23 | 2.73M shares derived: sum of 3 quarters · filed 2023-02-23 | 4.68M shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 410.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | 2.50M shares derived: sum of 2 quarters · filed 2022-11-01 | 4.45M shares 10-Q · filed 2022-11-01 | 4.96M shares derived: sum of 4 quarters · filed 2022-11-01 |
| 2022-06-30 | 2.09M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | 4.04M shares 10-Q · filed 2022-08-02 | 4.55M shares derived: sum of 3 quarters · filed 2022-08-02 | 5.26M shares derived: sum of 4 quarters · filed 2022-08-02 |
| 2022-03-31 | 1.95M shares 10-Q · filed 2022-05-03 | 2.46M shares derived: sum of 2 quarters · filed 2022-05-03 | 3.17M shares derived: sum of 3 quarters · filed 2022-05-03 | |
| 2021-12-31 | 511.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | 1.23M shares derived: sum of 2 quarters · filed 2022-02-24 | 4.29M shares 10-K · filed 2022-02-24 | |
| 2021-09-30 | 714.33K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | 3.78M shares 10-Q · filed 2021-11-02 | ||
| 2021-06-30 | 3.06M shares 10-Q · filed 2021-08-10 | |||
| 2020-12-31 | 3.70M shares 10-K · filed 2022-02-24 | |||
| 2020-06-30 | 0.00 shares 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |